Loading
A phase 2 trial of Artesunate vaginal insert in vaginal cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) is a phase 2 interventional study registered as NCT04098744 by Frantz Viral Therapeutics, LLC, with 78 participants planned, started 2020-09-09 and due to reach its primary completion in 2026-07-31. Interventions recorded: Artesunate vaginal insert and Placebo vaginal insert.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Frantz Viral Therapeutics and the tag pipeline.
Shares Vaginal cancer and the tag pipeline.
Shares Vaginal cancer and the tag pipeline.
Shares Frantz Viral Therapeutics, Vaginal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/